Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.O)

SUPN.O on Consolidated Issue listed on NASDAQ Global Market

33.25USD
26 Apr 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$33.25
Open
$33.00
Day's High
$33.65
Day's Low
$32.85
Volume
462,180
Avg. Vol
544,902
52-wk High
$33.65
52-wk Low
$14.14

SUPN.O

Chart for SUPN.O

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $1,652.85
Shares Outstanding(Mil.): 50.16
Dividend: --
Yield (%): --

Financials

  SUPN.O Industry Sector
P/E (TTM): 18.72 29.33 30.27
EPS (TTM): 1.76 -- --
ROI: 50.61 13.69 13.24
ROE: 65.21 14.64 14.40

BRIEF-Supernus receives final FDA approval for trokendi XR

* Supernus receives final FDA approval for trokendi XR for migraine prophylaxis in adults and adolescents

Apr 05 2017

BRIEF-Supernus announces settlement with Actavis on Trokendi XR patent litigation

* Supernus announces settlement with Actavis on Trokendi XR patent litigation

Mar 07 2017

BRIEF-Cadila Healthcare says Zydus announces settlement with Supernus on Trokendi XR extended-release capsules

* Says Zydus announces settlement with Supernus on Trokendi XR® (Topiramate) extended-release capsules

Mar 07 2017

BRIEF-Supernus announces settlement with Zydus on Trokendi XR patent litigation

* Supernus announces settlement with Zydus on Trokendi XR patent litigation

Mar 06 2017

BRIEF-Supernus Pharmaceuticals files for non-timely 10-K

* Supernus Pharmaceuticals Inc - files for non-timely 10-K Source text: (http://bit.ly/2ldW969) Further company coverage:

Mar 01 2017

BRIEF-Supernus Q4 earnings per share $0.26

* Supernus announces record fourth quarter and full year 2016 financial results

Feb 28 2017

BRIEF-Supernus announces issuance of eighth U.S. patent protecting Trokendi XR

* Supernus announces issuance of eighth U.S. Patent protecting Trokendi XR

Feb 08 2017

BRIEF-Supernus wins seventh patent for epilepsy drug Trokendi

* Supernus announces issuance of seventh u.s. Patent protecting Trokendi XR Source text for Eikon: Further company coverage:

Jan 30 2017

BRIEF-Supernus provides business update

* Supernus Pharmaceuticals Inc - net product sales for Q3 of 2016 were $55.6 million, a 44.1% increase over $38.6 million in same period last year

Nov 14 2016

BRIEF-Supernus Pharmaceuticals sees 2016 net product sales in range of $205 mln to $210 mln

* Sees 2016 net product sales in range of $205 million to $210 million

Nov 14 2016

More From Around the Web

Competitors

Earnings vs. Estimates